Ferring's Firmagon gets EU approval for prostate cancer
This article was originally published in Scrip
Executive Summary
Ferring Pharmaceuticals' novel prostate cancer drug Firmagon (degarelix) has been granted EU approval by the European Commission for the treatment of patients with advanced hormone-dependent prostate cancer.